Arcutis Biotherapeutics’ (ARQT) Buy Rating Reiterated at Needham & Company LLC
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They currently have a $20.00 target price on the stock. Needham & Company LLC’s price target suggests a potential upside of 35.78% from the stock’s current […]
Arcutis Biotherapeutics (NASDAQ:ARQT – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at Needham & Company LLC in a research report issued on Thursday,Benzinga reports. They currently have a $20.00 target price on the stock. Needham & Company LLC’s price target suggests a potential upside of 35.78% from the stock’s current […]
